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Apoptosis
The term "apoptosis" is derived from the Greek words "απο" and "πτωσιζ" 
meaning "dropping off" and refers to the falling of  leaves from trees in autumn.
Introduction
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Morphological 
changes in apoptosis
Morphological alterations of  apoptotic cell death that 
concern both the nucleus and the cytoplasm are 
Introduction
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remarkably similar across cell types 
and species
chromatin condensation and nuclear 
fragmentation,
which are accompanied by
1)rounding up of  the cell,
2)reduction in cellular volume (pyknosis)
3)retraction of  pseudopodes
Introduction
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Morphological hallmarks of  
apoptosis in the nucleus are
Chromatin condensation starts at the 
periphery of  the 
1)nuclear membrane, 
2)forming a crescent or 
3)ring-like structure
Introduction
8
9The chromatin further 
condenses
until it breaks up inside a cell 
with an intact membrane, a 
feature described as 
karyorrhexis
Introduction
he plasma membrane is
intact throughout the total 
process
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At the later stage of  apoptosis some of  the morphological features include
1)membrane blebbing
2) ultrastrutural modification of
cytoplasmic organelle
3)and a loss of  membrane 
integrity(1)
Introduction
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Biochemical changes in apoptosis
1) activation of  caspases, 
2) DNA and protein breakdown and
3) membrane changes and recognition by 
phagocytic cells
introducton
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Early in apoptosis
here is expression of  phosphatidylserine (PS) in the outer layers of  the cell membrane
which has been "flipped out" from the inner layers. This allows early recognition of  dead cells by 
macrophages,
resulting in phagocytosis without the release of  pro-inflammatory cellular components
Introduction
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This is followed by a 
characteristic
breakdown of  DNA into
large 50 to 300 
kilobase pieces
Introduction
Early in apoptosis
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Later
there is 
internucleosomal cleavage of  DNA
Introduction
into oligonucleosomes in multiples of
180 to 200 base pairs by 
Endonucleases(2)
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Another specific feature of
apoptosis is the activation of  a group of  enzymes belonging to
to the cysteine protease family named caspases. 
The "c" of  "caspase" refers to a cysteine protease, while the "aspase" 
refers to the enzyme's unique property to cleave after aspartic acid 
residues
Introduction
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Introduction
Activated caspases 1)cleave many vital cellular proteins
2)and break up the nuclear scaffold
and cytoskeleton. 
3)They also activate DNAase, which 
further degrade nuclear DNA(3)
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Introduction
Mechanisms of  apoptosis
. Caspases are central to the mechanism of  apoptosis as 
they are both the 
initiators and executioners
There are three pathways by which
caspases can be activated
18
Introduction
The two commonly 
described
initiation pathways 
are the
1)intrinsic (or mitochondrial)
2) and extrinsic (or death receptor)
3)A third less well-known initiation 
pathway is the intrinsic endoplasmic 
reticulum pathway(4)
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The extrinsic death receptor pathway
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Introduction
The extrinsic death receptor pathway
the best known death receptors is 
the type
1 TNF receptor (TNFR1)
and a related protein called Fas 
(CD95) 
and their ligands are called 
TNF and Fas ligand (FasL) 
respectively
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Introduction
These death 
receptors have an
1)intracellular death domain that recruits adapter 
proteins such as TNF receptor-
2)associated death domain (TRADD) and 
3)Fas-associated death domain (FADD), as well as 
cysteine proteases like caspase 8
The extrinsic death receptor pathway
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Introduction
the whole ligand-receptor-adaptor 
protein complex is known as
the death-inducing signalling complex 
(DISC)
DISC then initiates the 
assembly 
and activation of  pro-caspase 8
The extrinsic death receptor pathway
24
The intrinsic mitochondrial pathway
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Introduction
. Internal 
stimuli such as
1)irreparable genetic damage
2 )hypoxia,
3)extremely high concentrations of  
cytosolic Ca2+
4 )and severe oxidative stress are some 
triggers of  the initiation of  the intrinsic 
mitochondrial pathwa
The intrinsic mitochondrial pathway
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Introduction
Regardless 
of  the 
stimuli
this pathway is the result of
increased mitochondrial permeability
and the release 
of  pro-apoptotic molecules such as 
cytochrome-c into the cytoplasm
The intrinsic mitochondrial pathway
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Introduction
This pathway is closely regulated by a 
group of  proteins belonging to the 
Bcl-2 family, named after the BCL2 
gene originally observed at the
chromosomal breakpoint of  the 
translocation of  chromosome 18 to 14
in follicular non-Hodgkin lymphoma
The intrinsic mitochondrial pathway
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Introduction
There are two main 
groups of  the Bcl-2
proteins
1)namely the pro-apoptotic
proteins (e.g. Bax, Bak, Bad, 
Bcl-XBs, id, Bik, Bim and 
Hrk)
2)and the anti-apoptotic 
proteins (e.g. Bcl-2, Bcl-XL, 
Bcl-W, Bfl-1 and Mcl-1)
The intrinsic mitochondrial pathway
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Introduction
Other apoptotic factors that
are released from the mitochondrial 
intermembrane space into the cytoplasm include
1)apoptosis inducing factor (AIF)
2) second mitochondria-derived activator of  caspase 
(Smac)
3) direct IAP Binding protein with Low pI 
(DIABLO) 
4)and Omi/high temperature requirement protein A 
(HtrA2)
The intrinsic mitochondrial pathway
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Introduction
Cytoplasmic release of
cytochrome c activates caspase 3 via the 
formation of  
a complex known as apoptosome which is made 
up
1)cytochrome c
2)Apaf-1 
3)and caspase 9
The intrinsic mitochondrial pathway
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Introduction
The intrinsic mitochondrial pathway
Smac/DIABLO or Omi/HtrA2
promotes caspase activation by
binding to inhibitor of  apoptosis 
proteins (IAPs) 
which subsequently leads to disruption 
in the interaction of  IAPs with caspase-
3 or -9
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Introduction
The intrinsic endoplasmic reticulum pathway
It is believed to be 
caspase 12-dependent
and mitochondria-independent
When the ER is injured by
cellular stresses like
1)hypoxia
2)free radicals or
3)glucose starvation(5)
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Introduction
Disrupted balance of  
pro-apoptotic and 
anti-apoptotic
proteins
The Bcl-2 
family of  
proteins p53
(IAPs)
Reduced capsase activity
Impaired death receptor 
signaling(6)
Apoptosis and 
carcinogenesis
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Cancer therapy via 
The extrinsic death receptor pathway
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RhApo2L/TRAIL effectively 
induces apoptosis in vitro in a broad
spectrum of  cancer cell lines, 
including
Discussion
1)lung
2)colon
3)pancreas and 
4)lymphoma
.
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1)SCID
2)athymic nude mice bearing CRC
3)NSCLC
4)non-Hodgkin’s lymphoma 
(NHL) xenografts.
Discussion
RhApo2L/TRAIL also
has demonstrated 
single-agent activity in 
vivo in preclinical 
tumor
models based on
37
In the first of  two studies, 
cynomolgus monkeys were 
administered
rhApo2L/TRAIL at doses of.
Preclinical Safety of  
rhApo2L/TRAIL
Discussion
0, 
0.1, 
1.0,
or 10 mg/kg/d 
For
7 days
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Discussion
Preclinical Safety of  
rhApo2L/TRAIL
no evidence of  toxicity to any 
other
major organ system or tissue was 
detected.(6)
Neither detectable signs of  
liver toxicity nor changes in 
liver enzyme
activity were observed
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http://www.bloodjournal.org/content/110/12/4037?
sso-checked=true
LAST UPDETE:12/04/2017
Activity of  rhApo2L/TRAIL and rituximab
1)Mice (n = 12 mice/group) were then treated 
with vehicle (black x),
2)60 mg/kg rhApo2L/TRAIL (closed blue 
circle), 
3)4 mg/kg rituximab (open green triangle), 
4)10 mg/kg rituximab (open red square),
5)rhApo2L/TRAIL and 4 mg/kg rituximab 
(closed green triangle),
6)or rhApo2L/TRAIL and 10 mg/kg rituximab 
(closed red square).
40
The intrinsic mitochondrial pathway
Cancer therapy via 
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Oxidative stress is a 
biochemical condition 
that is
characterized by the 
imbalance between
Oxidative Stress
Discussion
the
presence of
relatively high levels of  toxic 
reactive
species
42
Discussion
Oxidative Stress
are organic or inorganic molecules
that have an odd number of  
electrons
1)reactive oxygen
species (ROS),
2)reactive nitrogen species (RNS),
3)and the antioxidative defense 
mechanisms.1–3
ROS and RNS
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http://www.in-corpore.ch/news/oxidative-stress-
nutrition/
Last update:2017/04/14
Oxidative Stress
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The biological functions of  
oxidative stress 
and its
potential role in cancer 
development and progression
Discussion
Oxidative Stress
have been investigated for 
several decades.
Cancer itself  induces 
oxidative stress
45
actually
ROS levels have been found 
to be significantly
higher and
Oxidative StressDiscussion
GPX and SOD activities 
significantly
lower in cancer patients than 
controls(7)
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47
It is well established that 
some chemotherapeutic
agents and radiation 
therapy
Discussion Oxidative Stress
generate ROS in
patients during cancer 
therapy
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Oxidative StressDiscussion
1)alkylating agents (e.g., 
cyclophosphamide,
ifosfamide)
2)anthracycline antibiotics
which affect nucleic acids (e.g., 
doxorubicin,
bleomycin) 
3)platinum compounds (e.g., cisplatin)
Chemotherapy agents can be 
divided into
several categories
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BCL2 is known to
Discussion
bcl2
1)prevent programmed cell death
2)increase
metastatic potential
3)and promote resistance to 
anticancer
therapy.
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bcl2
Discussion
G3139 is an antisense
phosphorothioate 
oligodeoxynucleotide 
that suppresses
BCL2 expression
High expression of  the 
BCL2 proto-oncogene is
found in various solid 
tumours
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bcl2
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Source: en.wikipedia.org/wiki/Bcl-2#/media/File:BCL-
2_human.png
Last updated:12/04/2017
bcl2
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BCL2 antisense therapy is 
well tolerated
Discussion
bcl2
The first
results of  a phase I dose-
escalation clinical trial 
evaluating
subcutaneous administration 
of  G3139(8)
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One of  the most advanced gene 
therapy agents used in the
treatment of  human cancer is
the replication-
incompetent
adenovirus that delivers 
a p53 expression 
cassette,
RPR/INGN201
Discussion
p53
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Preclinical studies in human cell 
lines and
animals with head and neck 
cancers have shown
Discussion
p53
that the
p53 gene contained in RPR/INGN201 is 
efficiently
transcribed and translated into p53 protein
56
p53
Discussion
and suppressed tumour
growth in animal xenografts of  
human SCCHN through the
apoptotic pathway and other 
effects, such as inhibition of
angiogenesis.(9)
Treatment with
RPR/INGN201
inhibited cell growth in human 
SCCHN
cell lines of  diverse p53 status
57https://pdb101.rcsb.org/motm/31
LAST UPDETED:12/04/2017
p53
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http://www.dailymail.co.uk/health/article-3173307
LAST UPDETED:12/04/2017
p53
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60
caspase-8 is mutated in 
different
types of  cancers
Soung and colleagues94 screened gastric
carcinomas (162 cases),
breast carcinomas (93 caspase),
non–
small cell lung cancers (NSCLC) (185 cases), 
and 88 acute
leukaemias (88 cases)
for mutations within the caspase-8 gene
using single strand conformation 
polymorphism (SSCP)
Discussion CASPASE FAMILY
61
https://en.wikipedia.org/wiki/Caspase_8#/media/Fil
e:Protein_CASP8_PDB_1f9e.png
LAST UPDETED:12/04/2017
CASPASE FAMILY
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They found that
the incidence of  caspase-8 
mutation in gastric cancer is
statistically higher than 
those of
NSCLC
breast cancer, 
and
acute leukaemias. 
Furthermore, all of  the 13 
mutations detected
were in advanced gastric 
cancers but not in early 
gastric cancers
Discussion
CASPASE FAMILY
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1)three missense, 
2)one in-frame deletion,
and 
3)five frameshift mutations in the coding sequences;
……………………………………….
4)two
mutations in the initiation codon; 
……………………………………..
5)three mutations in the
introns; and one mutation in the 3V untranslated region
The
mutations consisted of
Discussion
CASPASE FAMILY
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Pancreatic cancer is one of  the 
leading causes of  cancer related
death in the world. 
1)Smoking,
2)diabetes mellitus history,
3)alcohol drinking 
are risk factors for pancreatic
carcinogenesis
Discussion
CASPASE FAMILY
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Discussion
CASPASE FAMILY
It has been shown that 
pancreatic cancer cells
often present
1)non-functional CD95/Fas
2)and aberrant expression of  FasL
and this mechanism may contribute to 
the malignant
and often rapid course of  the disease
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caspase-3 was mutated in one 
case in
1)stomach adenocarcinoma
2)one case in lung cancer,
3)four cases in
colon cancer,
4)one case in hepatocellular
carcinoma, 
5)and one case
in multiple myeloma
Discussion CASPASE FAMILY
67
The mutations
consisted of
Discussion
CASPASE FAMILY
1)six missense
mutations, 
2)four silent mutations,
3)two mutations in the introns,
4)one mutation in the 59-untranslated 
region, 
5)and one mutation
in the 39-untranslated region.
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Caspase-9 is a virtually 
ubiquitous protease, 
constitutively
expressed in a variety of  fetal 
and adult human tissues
Mutational analysis 
of  caspase-9 was performed in 
neuroblastoma
tissues
Discussion
CASPASE FAMILY
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Silent
mutations were detected in two 
colorectal carcinomas and 
one
gastric carcinoma
Discussion
CASPASE FAMILY
They isolated genomic 
DNAs from normal and
tumour tissues of  the same 
patients
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In a case–control study, 
lung cancer patients and age and
gender matched healthy controls 
were investigated for caspase-9
promoter polymorphism in lung 
cancer
Discussion
CASPASE FAMILY
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Discussion
CASPASE FAMILY
They reported that the
-21263 GG genotype 
was associated with a 
significantly
decreased risk of  lung cancer 
compared with the -21263 AA 
or
the combined 21263 AA + AG 
genotype
72
They found that caspase-9
polymorphisms were significantly associated with the 
risk of
lung cancer in the smokers but not in the non-smokers, which
reflects a gene–environment interaction
Discussion
CASPASE FAMILY
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Discussion
CASPASE FAMILY
Such an interaction is
biologically plausible because 
smoking is a major risk factor 
for
lung cancer. 
It was also found that the association 
between
caspase-9 polymorphisms and the risk 
of  lung cancer was
statistically significant in the light 
smokers but not in the heavy
Smokers(10)
74
Result
Most of  what we know about apoptosis has been 
developed
and understood only recentlyThe core idea of
designing therapeutic drugs for cancer is based on the 
fact that
worn out or damaged cells commit suicide in order for 
the body
to continue to grow normally, maintaining a healthy 
number of
cells, whereas this phenomenon is greatly disturbed in 
cancer
cells.
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Result
we are still left with huge challenges to be 
overcome.
Development of  drugs that act either by 
blocking the action of
antiapoptotic proteins, such as IAPs, small-
molecule inhibitors
(antisense oligonucleotides), 
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Result
or by halting, hampering or
interference with the transcription of  RNA, such 
as small
interfering RNA, BH3 mimetic and some 
HDACi, holds robust
potential for use in cancer therapy; however, the 
hope to cure
cancer is yet to be seen
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